Join our daily newsletter At The Bell to receive exclusive market insights
- TALi Digital (TD1) appoints Dr Mary Elizabeth Brinson as Interim CEO in addition to her role as Chief Medical Officer
- Prior to joining Tali, Dr Brinson was the Vice President, Global Clinical Affairs, at medical device company Cochlear (COH)
- She was at Cochlear for 16 years where she was also Director of Quality, Clinical and Regulatory Services and Director of Clinical Services, Research and Professional Training
- Dr Brinson took over from former CEO and Managing Director Glenn Smith who resigned in March to focus on other priorities
- TALi ends the day 10 per cent in the green with shares trading at 1.1 cents
TALi Digital (TD1) has appointed Dr Mary Elizabeth Brinson as Interim CEO in addition to her role as Chief Medical Officer.
Prior to joining Tali, Dr Brinson was the Vice President, Global Clinical Affairs, at medical device company Cochlear (COH).
She was at Cochlear for 16 years where she was also Director of Quality, Clinical and Regulatory Services and Director of Clinical Services, Research and Professional Training.
Dr Brinson holes a Doctorate in Audiology from the University of Louisville in Kentucky, a Master of Business Administration from Rutgers University in New Jersey and a Bachelor’s degree in Audiology and Speech Pathology from the University of Georgia.
“We’re thrilled that Mary Beth has agreed to step up to the role of Interim Chief Executive
Officer in addition to her role as Chief Medical Officer,” Chair Sue MacLeman commented.
“Her experience leading teams at Cochlear, one of the world’s most successful medical devices businesses, will be invaluable as we work to make the benefits of TALi’s innovative digital therapeutic available to patients.”
Dr Brinson took over from former CEO and Managing Director Glenn Smith who resigned on March 31, 2022 to focus on other priorities.
TALi has ended the day 10 per cent in the green with shares trading at 1.1 cents.
